Tag Archives: personalized medicine

fight-crc-lisa-fund-awards-2014

7th Lisa Fund Grant Awarded to Dr. Ho-Chou Tu

7th Lisa Fund Grant Awarded to Dr. Ho-Chou Tu

Fight Colorectal Cancer is excited to announce that Dr. Ho-Chou Tu received our 7th Lisa Fund Fellowship Grant – a $50,000 award given to a late-stage colorectal cancer researcher. This award is distributed through the Lisa Fund in partnership with American Association of Cancer Research (AACR.) Dr. Tu is a research fellow at the Children’s Hospital in Boston. She plans to use the award to determine the relationship between the Lin28A/B gene and colon cancer progression and prognosis. She hopes that her research will lead to predictive biomarkers for prognosis of colon cancer and a potential therapeutic target aimed to reduce colon cancer progression. Dr. Tu, a native of Taiwan,

New-Year-by-Kate-150x150

“You Don’t Own Me….” But do you own part of my genes?

The U.S. Supreme Court heard arguments Monday in a case that both sides consider absolutely vital to the future of medical research. The case: Can a company take out a patent on a human gene? Or, as the company Myriad Genetics told the Court, not actually a patent on a gene, but a patent on isolated sections of DNA molecules that they synthetically re-create in the lab to make a test for the gene. Patents were created 150 years ago in the Constitution as temporary protection of new inventions, thus giving economic incentive for inventors. But there is a clear rule that you cannot patent “a product of nature.” During oral

Personalizing Personalized Medicine

On Monday, April 25th, Fight Colorectal Cancer held a free patient webinar that tackled the somewhat complex but fascinating topic of personalized medicine. Personalized medicine is what the cancer community calls treatments that are tailored to each patient’s genetic makeup. It is the future of cancer care and in some cases, it is already making a big difference in the ways patients are treated. You can learn about these cutting edge treatments and about emerging findings in an archive of the webinar below. Our thanks to Carolyn Grande, CRNP, AOCNP for leading the discussion. She a phenomenal educator on this topic and a member of our Medical Advisory Board. She graciously

Upcoming Patient Webinars Will Bring the Science to YOU

Fight Colorectal Cancer is giving you the opportunity to talk to researchers and medical professionals in April and May through online webinars designed to bring the science of treating colorectal cancer down to the personal. The latest news from the petri dish Wednesday, April 20, 2011 8 – 9 PM Eastern Dr. Rona Yaeger will discuss the research she has been conducting over the past year with the grant she received as part of Fight Colorectal Cancer’s Lisa Fund research program. Dr. Yaeger’s research focused on inhibiting the AKT pathway in colorectal cancer cells. She conducted basic research to determine how inhibitors to the pathway might affect cells of patients

Changes in Blood Magnesium Levels Predict Response to Erbitux

Hypomagnesemia, or reduced magnesium levels, is a side effect of Erbitux® (cetuximab) treatment.  Patients with colorectal cancer whose blood magnesium dropped the fastest also had the best response to Erbitux given with Camptosar® (irinotecan) . Italian researchers measured magnesium levels for 68 patients before treatment began and then 6 hours, 1 7, 14, 21, 50, and 92 days later.  After the seventh day, readings decreased consistently. Magnesium levels fell at least 20 percent for 25 patients by the third week.  More of these patients responded to treatment, they lived longer before their cancer got worse and had longer overall survival.

Top